SpringWorks Therapeutics Secures FDA Approval for Gomekli to Treat NF1-Related Tumors

SpringWorks Therapeutics, Gomekli, mirdametinib, FDA approval, neurofibromatosis type 1 (NF1), plexiform neurofibromas (PN), rare disease treatment, MEK inhibitor

Voyager Therapeutics Halts ALS Gene Therapy Development Due to Off-Target Effects

SOD1 ALS gene therapy, Off-target effects, VY9323, siRNA payload, TRACER capsid, Preclinical data, Drug development delay

FDA Issues Import Alerts for Two Chinese API Manufacturers Following Failed Inspections

FDA, import alert, Chinese API manufacturers, failed inspections, quality control, Wuhu Nuowei Chemistry, Chengdu Innovation Pharmaceutical